Please wait while the formulary information is being retrieved.
PROTONIX IV (PANTOPRAZOLE SODIUM)
- Gastric hypersecretion with systemic mastocytosis
- Gastroesophageal reflux disease
- Pathological gastric acid hypersecretory condition
- Zollinger-ellison syndrome
Protonix 40 mg intravenous solution
- Infuse 40 mg by intravenous route once daily
40 mg intravenous solution
- Infuse 40 mg by intravenous route once daily
pantoprazole 40 mg intravenous solution
- Infuse 40 mg by intravenous route once daily
Erosive esophagitis
- Infuse 40 mg over by intravenous route once daily for 10 days
- Infuse 40 mg by intravenous route once daily
Gastric hypersecretion with systemic mastocytosis
- Infuse 80 mg by intravenous route every 8 hours
- Infuse 80 mg by intravenous route every 12 hours
Gastroesophageal reflux disease
- Infuse 40 mg over by intravenous route once daily for 7 days
- Infuse 40 mg over by intravenous route once daily for 10 days
- Infuse 40 mg by intravenous route once daily
- Infuse 20 mg by intravenous route once daily
Zollinger-ellison syndrome
- Infuse 80 mg by intravenous route every 8 hours
- Infuse 80 mg by intravenous route every 12 hours
- atazanavir
- Complera
- Edurant
- emtricitab-rilpivirine-tenofov
- nelfinavir
- Reyataz
- rilpivirine
- Viracept
Contraindicated
- Bosulif
- bosutinib
- Cellcept
- Cellcept Intravenous
- dasatinib
- erlotinib
- itraconazole
- ketoconazole
- methotrexate sodium
- methotrexate sodium (PF)
- mycophenolate mofetil
- mycophenolate mofetil HCl
- nilotinib
- Noxafil
- Onmel
- posaconazole
- Sporanox
- Sporanox Pulsepak
- Sprycel
- Tarceva
- Tasigna
Severe
Moderate
- Adderall
- Adderall Xr
- Amphetamine Salt Combo
- Ceftin
- cefuroxime axetil
- Dexedrine Spansule
- dextroamphetamine
- dextroamphetamine-amphetamine
- Isentress
- Methotrexate (anti-rheumatic)
- Procentra
- raltegravir
- Rheumatrex
- Trexall
- Zenzedi
- None
Contraindicated
- Clostridium difficile infection
- Interstitial nephritis
- Subacute cutaneous lupus erythematosus
- Systemic lupus erythematosus
Severe
Moderate
- CYp2c19 poor metabolizer
- Fracture
- Hypomagnesemia
- Osteoporosis
- Vitamin b12 deficiency
PROTONIX IV (PANTOPRAZOLE SODIUM)
- Gastric hypersecretion with systemic mastocytosis
- Gastroesophageal reflux disease
- Pathological gastric acid hypersecretory condition
- Zollinger-ellison syndrome
- None
- Acute abdominal pain
- Arthralgias
- Diarrhea
- Dizziness
- Flatulence
- Headache disorder
- Nausea
- Vomiting
More Frequent
Severe
Less Severe
- None
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Agranulocytosis
- Anaphylaxis
- Angioedema
- Bronchospastic pulmonary disease
- Clostridium difficile infection
- Erythema multiforme
- Fracture
- Hepatic failure
- Hepatitis
- Hepatocellular damage
- Hypertriglyceridemia
- Hyponatremia
- Increased creatine kinase level
- Injection site sequelae
- Interstitial nephritis
- Jaundice
- Leukopenia
- Neutropenic disorder
- Pancytopenia
- Rhabdomyolysis
- Stevens-johnson syndrome
- Subacute cutaneous lupus erythematosus
- Systemic lupus erythematosus
- Thrombocytopenic disorder
- Toxic epidermal necrolysis
Less Severe
- Acute confusion
- Benign fundic gland polyposis of stomach
- Blurred vision
- Constipation
- Drowsy
- Dysgeusia
- Fatigue
- General weakness
- Hallucinations
- Hypercholesterolemia
- Hypomagnesemia
- Insomnia
- Loss of taste
- Malaise
- Myalgias
- Pain
- Pruritus of skin
- Skin rash
- Thrombophlebitis
- Urticaria
- Vertigo
- Xerostomia
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Pantoprazole (IV)
Safety and efficacy of intravenous formulation not established.
- 1 Day – 18 Years
- Safety and efficacy of intravenous formulation not established.
Pantoprazole
- Severity Level:
2
- Additional Notes: Available human data show no increased risk for major birth defects.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Pantoprazole
Limited data suggest low amounts excreted with no known adverse infant effect
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Not known; no or inclusive data | Limited data suggest low amounts excreted with no known adverse infant effect |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Gastric hypersecretion with systemic mastocytosis | |
| C96.21 | Aggressive systemic mastocytosis |
| D47.02 | Systemic mastocytosis |
| K31.89 | Other diseases of stomach and duodenum |
| Gastroesophageal reflux disease | |
| K21 | Gastro-esophageal reflux disease |
| K21.0 | Gastro-esophageal reflux disease with esophagitis |
| K21.9 | Gastro-esophageal reflux disease without esophagitis |
| Pathological gastric acid hypersecretory condition | |
| K31.89 | Other diseases of stomach and duodenum |
| Zollinger-ellison syndrome | |
| E16.4 | Increased secretion of gastrin |
| 0-9 | A-Z |
|---|---|
| C96.21 | Aggressive systemic mastocytosis |
| D47.02 | Systemic mastocytosis |
| E16.4 | Increased secretion of gastrin |
| K21 | Gastro-esophageal reflux disease |
| K21.0 | Gastro-esophageal reflux disease with esophagitis |
| K21.9 | Gastro-esophageal reflux disease without esophagitis |
| K31.89 | Other diseases of stomach and duodenum |
| K31.89 | Other diseases of stomach and duodenum |
Formulary Reference Tool